Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20939371 | 1.00 | CHRM2 (0.47) | CHRM2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20384062 | 0.94 | CHRM2 (0.45) | CHRM2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2274269 | 0.94 | CHRM2 (0.45) | CHRM2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL17888212 | 0.88 | ALDH1A1 (0.45) | CHRM2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2274680 | 0.87 | ALDH1A1 (0.36) | CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL3436941 | 0.85 | ALDH1A1 (0.46) | CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL24781112 | 0.83 | CHRM2 (0.40) | CHRM2CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL16063078 | 0.82 | CYP1A2 (0.46) | CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL16063087 | 0.82 | CYP1A2 (0.46) | CHRM2ALDH1A1L3MBTL1 | |
| SCHEMBL15918974 | 0.81 | ALDH1A1 (0.48) | CHRM2L3MBTL3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512858-B1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4242211-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022100727-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-05-19 | — | — | WO | disclosed |
| WO-2021259309-A1 | GLP-1 RECEPTOR AGONIST, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| EP-3805234-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceultica nv (BE) | 2019-07-18 | — | — | US | disclosed |
| WO-2018050684-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | CHRM2 4569/4885CHRNB4 4435/4885CHRNA3 3992/4885 |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | CHRM2 4569/4885CHRNB4 4435/4885CHRNA3 3992/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHRM2 4704/4885CHRNB4 3026/4885CHRNA3 3830/4885 |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | CHRM2 4569/4885CHRNB4 4435/4885CHRNA3 3992/4885 |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | CHRM2 4569/4885CHRNB4 4435/4885CHRNA3 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.